4PanC, ShangS, KirchW, et al. Burden of diabetes in the adult Chinese population: a systematic literature review and future projections[J]. Int J Gen Med, 2010, 3:173–179.
5KhutsoaneD, SharmaSK, AlmustafaM, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study[J]. Diabetes Obes Metab, 2008, 10(3):212–222.
6KhamsehME, HaddadJ, YangW, et al. Safety and effectiveness of biphasic insulin aspart 30 in different age-groups: A1chieve sub-analysis[J]. Diabetes Ther, 2013, 4(2): 347–361.
7LeeKH, SeoSJ, Smith-PalmerJ, et al. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea [J]. Value Health, 2009, 12Suppl 3: S55–61.
8PalmerJL, KnudsenMS, AagrenM, et al. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting[J]. J Med Econ, 2010, 13(2):212–220.
9PalmerJL, GibbsM, ScheijbelerHW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China[J]. Adv Ther, 2008, 25(8): 752–774.
10HomeP, NaggarNE, KhamsehM, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study[J]. Diabetes Res Clin Pract, 2011, 94(3):352–363.
